<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04015232</url>
  </required_header>
  <id_info>
    <org_study_id>0554-17</org_study_id>
    <nct_id>NCT04015232</nct_id>
  </id_info>
  <brief_title>Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.</brief_title>
  <official_title>An Assessor-blind, Balanced, Parallel, Randomized, Two-treatment, Comparative Immunogenicity Study of Multiple Doses of INTP5 of Intas Pharmaceuticals Limited, India Against Neulasta® of Amgen Inc., USA Administered Subcutaneously in Healthy, Adult, Human Subjects Under Fed Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intas Pharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lambda Therapeutic Research Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Intas Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was an assessor-blind, balanced, parallel, randomized, two-treatment, comparative
      immunogenicity study of multiple doses of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6
      mL; Intas Pharmaceuticals Ltd. proposed biosimilar INTP5 compared to innovator product,
      US-Neulasta) in healthy, adult, human subjects under fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Actual">June 5, 2018</completion_date>
  <primary_completion_date type="Actual">June 5, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The study staff taking care of subject's safety and the laboratory personnel doing the sample analysis of PK, PD, and immunogenicity data were blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity Screening Incidence to Detect the Presence of Anti-PegG-CSF Antibodies.</measure>
    <time_frame>Samples (8 mL each) were withdrawn at screening, at pre-dose and at 336 (D-15, Week 2), 504 (D-22, Week 3, within 60 minutes before 2nd dose), 840 (D-36, Week 5), 1176 (D-50, Week 7), 1680 (D-71, Week 10) and 2016 (D-85, Week 12) hours after first dose.</time_frame>
    <description>Immunogenicity (anti-drug antibody; ADA) data is presented for all subjects' samples collected and a descriptive analysis is provided for immunogenicity (ADA) data.
Percentage incidence within + 10% of the expected ADA positivity incidence of Test (6% ADA in Test is anticipated from literature) is not considered clinically significant.
Evaluation of immunogenicity is carried out in a tiered fashion:
Screening assay to assess if samples were positive or negative for anti-PegG-CSF.
Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim.
Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples.
Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Endpoints: Pegfilgrastim C[Max]</measure>
    <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
    <description>Pharmacokinetic (PK) properties of the test and reference formulations were assessed by measuring serum Pegfilgrastim concentration.
Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoints: Pegfilgrastim AUC[0-t]</measure>
    <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
    <description>Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoints: Pegfilgrastim AUC[0-∞]</measure>
    <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
    <description>Area under the serum concentration versus time curve from time zero to infinity. Where AUC[0-infinity]= AUC[0-t] + Ct/lambda-z, Ct is the last measurable concentration and lamda-z is the terminal rate constant. AUC[0-infinity] is the sum of measurable and extrapolated parts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoints: Pegfilgrastim T[Max]</measure>
    <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
    <description>The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoints: Pegfilgrastim λz (Lambda-z)</measure>
    <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
    <description>Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoints: Pegfilgrastim R^2 Adjusted</measure>
    <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
    <description>Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz (lambda-z). R^2 is the coefficient of determination and can range from 0 to 1, with higher values indicating greater predictability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs]</measure>
    <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
    <description>The residual area in percentage determined by the formula, [(AUC[0-infinity]-AUC[0-t])/AUC[0-infinity]] x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Endpoints: Pegfilgrastim t[1/2]</measure>
    <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
    <description>The terminal half-life calculated using the formula 0.693/(lambda-z)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoints for Baseline Non-adjusted ANC: E[Max]</measure>
    <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
    <description>Maximum measured absolute neutrophil count (ANC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoints for Baseline Non-adjusted ANC: T[Max]</measure>
    <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
    <description>Area under the ANC versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoints for Baseline Non-adjusted ANC: AUEC[0-t]</measure>
    <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
    <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoints for Baseline Adjusted ANC: E[Max]</measure>
    <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
    <description>Maximum measured absolute neutrophil count (ANC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoints for Baseline Adjusted ANC: AUEC[0-t]</measure>
    <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
    <description>Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoints for Baseline Adjusted ANC: T[Max]</measure>
    <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
    <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoints for Baseline Adjusted ANC: λz (Lambda-z)</measure>
    <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
    <description>First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more non-zero plasma concentration values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Endpoints for Baseline Adjusted ANC: t[1/2]</measure>
    <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
    <description>The terminal half-life will be calculated as 0.693/(lambda-z)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Immunogenicity</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>INTP5 biosimilar product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Neulasta reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>INTP5</intervention_name>
    <description>INTP5, a pegfilgrastim biosimilar to US Neulasta.</description>
    <arm_group_label>INTP5 biosimilar product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>US Neulasta</intervention_name>
    <description>US Neulasta: FDA approved pegfilgrastim innovator product.</description>
    <arm_group_label>US Neulasta reference product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive)
             living in and around Ahmedabad city or western part of India.

          2. Having body weight ≥50 kg and body mass index (BMI) between 18.5 and 29.9 (both
             inclusive), calculated as weight in kg/height in meter^2.

          3. Not having any significant disease in medical history or clinically significant
             abnormal findings during screening, abdominal ultrasonography, medical history,
             clinical examination, laboratory evaluations, 12-lead echocardiogram (ECG) and chest
             X-ray (posterior-anterior view; within the last 6 months) recordings.

          4. Able to understand and comply with the study procedures, in the opinion of the
             investigator.

          5. Able to give voluntary written informed consent for participation in the trial.

          6. In case of female subjects:

               -  Surgically sterilized at least 6 months prior to study participation; Or If a
                  woman of child bearing potential is willing to use a suitable and effective
                  double barrier contraceptive method or intra uterine device during the study.

               -  Serum pregnancy test (for female subjects) must be negative.

        Exclusion criteria:

          1. Known hypersensitivity to the study drug or its constituents and/or hypersensitivity
             to E. coli derived proteins, and/or previous exposure to the study drug.

          2. History or presence of any disease or condition which might compromise the
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,
             immunological, dermatological, gastrointestinal or any other body system.

          3. Known case of hereditary fructose intolerance.

          4. Subjects with latex allergies will be excluded as the needle cover on the single-use
             prefilled syringe contains dry natural rubber (latex).

          5. Any clinically significant laboratory finding including absolute neutrophil count
             (ANC), platelet, red blood cells (RBC) count, and hemoglobin level at the time of
             screening.

          6. Prior exposure to any peptide colony stimulating or growth factor, including
             erythropoietin, filgrastim or Pegfilgrastim; Prior exposure to any vaccines,
             immunoglobulin preparations or immunomodulators within the past 6 months prior to
             receiving first dose; evidence of E. coli diarrhea or diseases within 3 months.

          7. Any history or presence of asthma (including aspirin-induced asthma) or nasal polyp or
             NSAIDs induced urticaria.

          8. Subjects with a history of pulmonary infiltrate or pneumonia in the last 6 months.

          9. History of any hematologic disease including sickle cell disorders.

         10. Ingestion or use of any prescribed medication at any time within 1 month prior to
             receiving first dose.

         11. Receipt of over-the-counter medicines which have not yet cleared from the body (5
             half-lives must have passed for the medicine to be considered to have cleared from the
             body).

         12. A recent history of harmful use of alcohol, i.e. alcohol consumption of more than 14
             standard drinks per week for men and more than 7 standard drinks per week for women (A
             standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40%
             distilled spirits, such as rum, whisky, brandy etc.) or consumption of alcohol or
             alcoholic products within 72 hours prior to receiving study medicine.

         13. Smokers, who smoke 10 or more than 10 cigarettes/day or inability to abstain from
             smoking during the study.

         14. Use of any recreational drugs or history of drug addiction or testing positive in
             pre-study drug scans.

         15. Donation of blood (1 unit or 350 mL) or equivalent amount of blood substitute.

         16. Receipt of an investigational medicinal product or participation in a drug research
             study within a period of 90 days prior to the first dose of study medication.
             Elimination half-life of the study drug should be taken into consideration for
             inclusion of the subject in the study.

         17. Positive result for human immunodeficiency virus (HIV I &amp;/or II) and/or hepatitis B
             and C tests.

         18. History or presence of cancer because of which anticipated life span is less than 5
             years as per the investigator's assessment.

         19. History or presence of psychiatric disorders.

         20. Presence of tattoo or scars or any type of skin lesions due to infection, burning,
             wound or inflammation at the proposed site of injection.

         21. An unusual diet, for whatever reason (e.g. low-sodium), for 4 weeks prior to receiving
             the study medicine. In any such case, subject selection will be at the discretion of
             the Principal Investigator.

         22. Consumption of grape fruit or grape fruit products within 72 hours prior to receiving
             study drug.

         23. A history of difficulty in donating blood.

         24. Females, pregnant or lactating, or planning to become pregnant during the time the
             subject is on study or found positive in pregnancy test at screening.

         25. Any infections in the last 4 weeks before receiving study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adarsh K Garg, M.B.B.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinu Jose, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Intas Pharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gota</state>
        <zip>382481</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <results_first_submitted>July 19, 2019</results_first_submitted>
  <results_first_submitted_qc>September 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2019</results_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pegfilgrastim</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>Healthy Volunteers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04015232/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04015232/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>INTP5 Biosimilar Product</title>
          <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
        </group>
        <group group_id="P2">
          <title>US Neulasta Reference Product</title>
          <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical Grounds</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>INTP5 Biosimilar Product</title>
          <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
        </group>
        <group group_id="B2">
          <title>US Neulasta Reference Product</title>
          <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="6.82"/>
                    <measurement group_id="B2" value="34.3" spread="6.05"/>
                    <measurement group_id="B3" value="32.9" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160.2" spread="8.48"/>
                    <measurement group_id="B2" value="160.1" spread="8.68"/>
                    <measurement group_id="B3" value="160.2" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="8.31"/>
                    <measurement group_id="B2" value="62.6" spread="7.49"/>
                    <measurement group_id="B3" value="61.9" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.95" spread="3.069"/>
                    <measurement group_id="B2" value="24.51" spread="3.266"/>
                    <measurement group_id="B3" value="24.23" spread="3.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity Screening Incidence to Detect the Presence of Anti-PegG-CSF Antibodies.</title>
        <description>Immunogenicity (anti-drug antibody; ADA) data is presented for all subjects' samples collected and a descriptive analysis is provided for immunogenicity (ADA) data.
Percentage incidence within + 10% of the expected ADA positivity incidence of Test (6% ADA in Test is anticipated from literature) is not considered clinically significant.
Evaluation of immunogenicity is carried out in a tiered fashion:
Screening assay to assess if samples were positive or negative for anti-PegG-CSF.
Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim.
Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples.
Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.</description>
        <time_frame>Samples (8 mL each) were withdrawn at screening, at pre-dose and at 336 (D-15, Week 2), 504 (D-22, Week 3, within 60 minutes before 2nd dose), 840 (D-36, Week 5), 1176 (D-50, Week 7), 1680 (D-71, Week 10) and 2016 (D-85, Week 12) hours after first dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Biosimilar Product</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>US Neulasta Reference Product</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Screening Incidence to Detect the Presence of Anti-PegG-CSF Antibodies.</title>
          <description>Immunogenicity (anti-drug antibody; ADA) data is presented for all subjects' samples collected and a descriptive analysis is provided for immunogenicity (ADA) data.
Percentage incidence within + 10% of the expected ADA positivity incidence of Test (6% ADA in Test is anticipated from literature) is not considered clinically significant.
Evaluation of immunogenicity is carried out in a tiered fashion:
Screening assay to assess if samples were positive or negative for anti-PegG-CSF.
Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim.
Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples.
Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive for Anti-Drug-Antibody</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive in Neutralizing Anti-Drug-Antibody</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Anit-Drug Antibody Confirmed Positive Results</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoints: Pegfilgrastim C[Max]</title>
        <description>Pharmacokinetic (PK) properties of the test and reference formulations were assessed by measuring serum Pegfilgrastim concentration.
Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
        <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
        <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta.</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoints: Pegfilgrastim C[Max]</title>
          <description>Pharmacokinetic (PK) properties of the test and reference formulations were assessed by measuring serum Pegfilgrastim concentration.
Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
          <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="483.230" spread="175.1787"/>
                    <measurement group_id="O2" value="346.018" spread="150.4879"/>
                    <measurement group_id="O3" value="368.569" spread="223.3380"/>
                    <measurement group_id="O4" value="371.778" spread="263.4440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoints: Pegfilgrastim AUC[0-t]</title>
        <description>Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.</description>
        <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
        <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoints: Pegfilgrastim AUC[0-t]</title>
          <description>Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.</description>
          <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22417.938" spread="9922.2648"/>
                    <measurement group_id="O2" value="13640.695" spread="6709.2752"/>
                    <measurement group_id="O3" value="16610.870" spread="11255.1296"/>
                    <measurement group_id="O4" value="15255.327" spread="11050.7580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoints: Pegfilgrastim AUC[0-∞]</title>
        <description>Area under the serum concentration versus time curve from time zero to infinity. Where AUC[0-infinity]= AUC[0-t] + Ct/lambda-z, Ct is the last measurable concentration and lamda-z is the terminal rate constant. AUC[0-infinity] is the sum of measurable and extrapolated parts.</description>
        <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
        <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoints: Pegfilgrastim AUC[0-∞]</title>
          <description>Area under the serum concentration versus time curve from time zero to infinity. Where AUC[0-infinity]= AUC[0-t] + Ct/lambda-z, Ct is the last measurable concentration and lamda-z is the terminal rate constant. AUC[0-infinity] is the sum of measurable and extrapolated parts.</description>
          <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22436.497" spread="9922.4383"/>
                    <measurement group_id="O2" value="13637.403" spread="6699.9736"/>
                    <measurement group_id="O3" value="16630.861" spread="11253.7406"/>
                    <measurement group_id="O4" value="15280.376" spread="11058.1142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoints: Pegfilgrastim T[Max]</title>
        <description>The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
        <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
        <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoints: Pegfilgrastim T[Max]</title>
          <description>The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.</description>
          <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.405" spread="3.3758"/>
                    <measurement group_id="O2" value="20.800" spread="5.5936"/>
                    <measurement group_id="O3" value="22.226" spread="3.5298"/>
                    <measurement group_id="O4" value="23.111" spread="2.6667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoints: Pegfilgrastim λz (Lambda-z)</title>
        <description>Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.</description>
        <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
        <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoints: Pegfilgrastim λz (Lambda-z)</title>
          <description>Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.</description>
          <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.0071"/>
                    <measurement group_id="O2" value="0.025" spread="0.0142"/>
                    <measurement group_id="O3" value="0.022" spread="0.0058"/>
                    <measurement group_id="O4" value="0.019" spread="0.0074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoints: Pegfilgrastim R^2 Adjusted</title>
        <description>Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz (lambda-z). R^2 is the coefficient of determination and can range from 0 to 1, with higher values indicating greater predictability.</description>
        <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
        <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoints: Pegfilgrastim R^2 Adjusted</title>
          <description>Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz (lambda-z). R^2 is the coefficient of determination and can range from 0 to 1, with higher values indicating greater predictability.</description>
          <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
          <units>Coefficient of Determination</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.968" spread="0.0379"/>
                    <measurement group_id="O2" value="0.876" spread="0.133"/>
                    <measurement group_id="O3" value="0.974" spread="0.0245"/>
                    <measurement group_id="O4" value="0.879" spread="0.2339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs]</title>
        <description>The residual area in percentage determined by the formula, [(AUC[0-infinity]-AUC[0-t])/AUC[0-infinity]] x 100.</description>
        <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
        <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs]</title>
          <description>The residual area in percentage determined by the formula, [(AUC[0-infinity]-AUC[0-t])/AUC[0-infinity]] x 100.</description>
          <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
          <units>percentage of AUC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.115" spread="0.1106"/>
                    <measurement group_id="O2" value="0.644" spread="1.4428"/>
                    <measurement group_id="O3" value="0.230" spread="0.2672"/>
                    <measurement group_id="O4" value="0.266" spread="0.2664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Endpoints: Pegfilgrastim t[1/2]</title>
        <description>The terminal half-life calculated using the formula 0.693/(lambda-z)</description>
        <time_frame>Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.</time_frame>
        <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Endpoints: Pegfilgrastim t[1/2]</title>
          <description>The terminal half-life calculated using the formula 0.693/(lambda-z)</description>
          <population>All the 19 ADA confirmed positive subjects were included in the PK analysis: 10 subjects from INTP5 and 9 subjects from US-Neulasta</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.721" spread="11.0052"/>
                    <measurement group_id="O2" value="36.612" spread="19.6215"/>
                    <measurement group_id="O3" value="34.172" spread="8.8669"/>
                    <measurement group_id="O4" value="40.616" spread="14.6054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoints for Baseline Non-adjusted ANC: E[Max]</title>
        <description>Maximum measured absolute neutrophil count (ANC).</description>
        <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
        <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoints for Baseline Non-adjusted ANC: E[Max]</title>
          <description>Maximum measured absolute neutrophil count (ANC).</description>
          <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
          <units>x10^3cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA-NEGATIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.72" spread="10.862"/>
                    <measurement group_id="O2" value="44.63" spread="11.077"/>
                    <measurement group_id="O3" value="38.34" spread="9.925"/>
                    <measurement group_id="O4" value="40.62" spread="8.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-POSITIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.89" spread="10.512"/>
                    <measurement group_id="O2" value="46.53" spread="9.093"/>
                    <measurement group_id="O3" value="38.38" spread="8.211"/>
                    <measurement group_id="O4" value="44.96" spread="16.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoints for Baseline Non-adjusted ANC: T[Max]</title>
        <description>Area under the ANC versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
        <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
        <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoints for Baseline Non-adjusted ANC: T[Max]</title>
          <description>Area under the ANC versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
          <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA-NEGATIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.710" spread="11.1076"/>
                    <measurement group_id="O2" value="59.587" spread="14.9170"/>
                    <measurement group_id="O3" value="63.182" spread="15.8763"/>
                    <measurement group_id="O4" value="64.637" spread="20.5772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-POSITIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.003" spread="0.0072"/>
                    <measurement group_id="O2" value="67.453" spread="15.7091"/>
                    <measurement group_id="O3" value="64.002" spread="12.0014"/>
                    <measurement group_id="O4" value="61.461" spread="29.9401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoints for Baseline Non-adjusted ANC: AUEC[0-t]</title>
        <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
        <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
        <population>Table breaks participants into ADA(-) or ADA(+), totaling the overall number of participants by arm. 5 Subjects having three consecutive missing samples in elimination phase were excluded from the analysis of AUEC0-t reducing the total participants to 88 for INTP5 Dose 1, 88 for INTP5 Dose 2, 92 for Neulasta Dose 1, and 91 for Neulasta Dose 2.</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoints for Baseline Non-adjusted ANC: AUEC[0-t]</title>
          <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
          <population>Table breaks participants into ADA(-) or ADA(+), totaling the overall number of participants by arm. 5 Subjects having three consecutive missing samples in elimination phase were excluded from the analysis of AUEC0-t reducing the total participants to 88 for INTP5 Dose 1, 88 for INTP5 Dose 2, 92 for Neulasta Dose 1, and 91 for Neulasta Dose 2.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA-NEGATIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7107.14" spread="1481.971"/>
                    <measurement group_id="O2" value="7929.25" spread="1561.246"/>
                    <measurement group_id="O3" value="6718.70" spread="1361.957"/>
                    <measurement group_id="O4" value="7359.09" spread="1455.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-POSITIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7286.53" spread="1744.737"/>
                    <measurement group_id="O2" value="8539.99" spread="1522.935"/>
                    <measurement group_id="O3" value="6846.77" spread="763.675"/>
                    <measurement group_id="O4" value="7761.65" spread="1658.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoints for Baseline Adjusted ANC: E[Max]</title>
        <description>Maximum measured absolute neutrophil count (ANC).</description>
        <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
        <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoints for Baseline Adjusted ANC: E[Max]</title>
          <description>Maximum measured absolute neutrophil count (ANC).</description>
          <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
          <units>x10^3cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA-NEGATIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.50" spread="10.458"/>
                    <measurement group_id="O2" value="40.80" spread="11.038"/>
                    <measurement group_id="O3" value="33.35" spread="9.189"/>
                    <measurement group_id="O4" value="36.56" spread="8.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-POSITIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.37" spread="9.548"/>
                    <measurement group_id="O2" value="42.50" spread="10.061"/>
                    <measurement group_id="O3" value="34.18" spread="8.503"/>
                    <measurement group_id="O4" value="40.76" spread="17.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoints for Baseline Adjusted ANC: AUEC[0-t]</title>
        <description>Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
        <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
        <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoints for Baseline Adjusted ANC: AUEC[0-t]</title>
          <description>Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.</description>
          <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
          <units>x10^3cells*h/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA-NEGATIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4920.26" spread="1339.674"/>
                    <measurement group_id="O2" value="5992.49" spread="1555.062"/>
                    <measurement group_id="O3" value="4389.55" spread="1140.655"/>
                    <measurement group_id="O4" value="5441.01" spread="1478.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-POSITIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4967.86" spread="1229.792"/>
                    <measurement group_id="O2" value="6539.58" spread="2202.473"/>
                    <measurement group_id="O3" value="4578.32" spread="1200.125"/>
                    <measurement group_id="O4" value="5676.92" spread="1991.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoints for Baseline Adjusted ANC: T[Max]</title>
        <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
        <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
        <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoints for Baseline Adjusted ANC: T[Max]</title>
          <description>Time to reach the maximum measured absolute neutrophil count (ANC)</description>
          <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA-NEGATIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.617" spread="11.1482"/>
                    <measurement group_id="O2" value="59.735" spread="14.9546"/>
                    <measurement group_id="O3" value="65.553" spread="15.8887"/>
                    <measurement group_id="O4" value="65.043" spread="20.6610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-POSITIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.003" spread="0.0072"/>
                    <measurement group_id="O2" value="67.453" spread="15.7091"/>
                    <measurement group_id="O3" value="64.002" spread="12.0014"/>
                    <measurement group_id="O4" value="61.461" spread="29.9401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoints for Baseline Adjusted ANC: λz (Lambda-z)</title>
        <description>First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more non-zero plasma concentration values.</description>
        <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
        <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoints for Baseline Adjusted ANC: λz (Lambda-z)</title>
          <description>First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more non-zero plasma concentration values.</description>
          <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA-NEGATIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.007"/>
                    <measurement group_id="O2" value="0.01" spread="0.006"/>
                    <measurement group_id="O3" value="0.01" spread="0.006"/>
                    <measurement group_id="O4" value="0.01" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-POSITIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.006"/>
                    <measurement group_id="O2" value="0.01" spread="0.003"/>
                    <measurement group_id="O3" value="0.01" spread="0.004"/>
                    <measurement group_id="O4" value="0.01" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD Endpoints for Baseline Adjusted ANC: t[1/2]</title>
        <description>The terminal half-life will be calculated as 0.693/(lambda-z)</description>
        <time_frame>Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.</time_frame>
        <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
        <group_list>
          <group group_id="O1">
            <title>INTP5 Dose 1</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
          </group>
          <group group_id="O2">
            <title>INTP5 Dose 2</title>
            <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta</description>
          </group>
          <group group_id="O3">
            <title>US Neulasta Dose 1</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
          <group group_id="O4">
            <title>US Neulasta Dose 2</title>
            <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
          </group>
        </group_list>
        <measure>
          <title>PD Endpoints for Baseline Adjusted ANC: t[1/2]</title>
          <description>The terminal half-life will be calculated as 0.693/(lambda-z)</description>
          <population>Outcome Measure Data Table is breaks participants into negative-ADA or positive-ADA, totaling the overall number of participants by arm</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA-NEGATIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.25" spread="28.847"/>
                    <measurement group_id="O2" value="64.13" spread="26.785"/>
                    <measurement group_id="O3" value="77.23" spread="86.239"/>
                    <measurement group_id="O4" value="76.02" spread="59.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA-POSITIVE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.03" spread="41.296"/>
                    <measurement group_id="O2" value="69.72" spread="25.447"/>
                    <measurement group_id="O3" value="81.74" spread="29.981"/>
                    <measurement group_id="O4" value="67.02" spread="22.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>99 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>INTP5 Biosimilar Product</title>
          <description>INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
INTP5: A pegfilgrastim biosimilar to US Neulasta.</description>
        </group>
        <group group_id="E2">
          <title>US Neulasta Reference Product</title>
          <description>US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
US Neulasta: FDA approved pegfilgrastim innovator product.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>There was 1 death reported. The subject died due to accidental drowning. The AE was severe in nature and the relationship of the AE to the study drug was considered as not related. Apart from the death, no other SAEs were reported during the study.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Human chorionic gonadotropin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Rash generalized</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adarsh Kumar Garg, M.B.B.S. Principal Investigator</name_or_title>
      <organization>Lambda Therapeutic Research Ltd.</organization>
      <phone>+91-79-40202020</phone>
      <email>adarshgarg@lambda-cro.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

